RT Journal Article
SR Electronic
T1 Incidence and etiology of clinically-attended, antibiotic-treated diarrhea among children under five years of age in low- and middle-income countries: evidence from the Global Enteric Multicenter Study
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.05.11.20098640
DO 10.1101/2020.05.11.20098640
A1 Lewnard, Joseph A.
A1 McQuade, Elizabeth T. Rogawski
A1 Platts-Mills, James A.
A1 Kotloff, Karen L.
A1 Laxminarayan, Ramanan
YR 2020
UL http://medrxiv.org/content/early/2020/05/18/2020.05.11.20098640.abstract
AB Background Diarrhea is a leading cause of antibiotic consumption among children in low- and middle-income countries. While vaccines may prevent diarrhea infections for which children often receive antibiotics, the contribution of individual enteropathogens to antibiotic use is minimally understood. We used data from the Global Enteric Multicenter Study (GEMS) to estimate pathogen-specific incidence of antibiotic-treated diarrhea among children under five years old residing in six countries of sub-Saharan Africa and South Asia before rotavirus vaccine implementation.Methods and findings GEMS was an age-stratified, individually-matched case-control study. Stool specimens were obtained from children presenting to sentinel health clinics with newly-onset, acute diarrhea (including moderate-to-severe and less-severe diarrhea) as well as matched community controls without diarrhea. We used data from conventional and quantitative molecular diagnostic assays applied to stool specimens to estimate the proportion of antibiotic-treated diarrhea cases attributable to each pathogen. Antibiotics were administered or prescribed to 9,606 of 12,109 moderate-to-severe cases and 1,844 of 3,174 less-severe cases. Across all sites, incidence rates of clinically-attended, antibiotic-treated diarrhea were 12.2 (95% confidence interval: 9.0-17.8), 10.2 (7.4-13.9) and 1.9 (1.3-3.0) episodes per 100 child-years at risk at ages 6 weeks to 11 months, 12-23 months, and 24-59 months, respectively. Based on the recommendation for antibiotic treatment to be reserved for cases with dysentery, we estimated a ratio of 12.6 (8.6-20.8) inappropriately-treated diarrhea cases for each appropriately-treated case. Rotavirus, adenovirus serotypes 40/41, Shigella, sapovirus, Shiga toxin-producing Escherichia coli, and Cryptosporidium were the leading antibiotic-treated diarrhea etiologies. Rotavirus caused 29.2% (24.5-35.2%) of antibiotic-treated cases, including the largest share in both the first and second years of life. Shigella caused 14.9% (11.4-18.9%) of antibiotic-treated cases, and was the leading etiology at ages 24-59 months.Conclusions Our findings should inform the prioritization of vaccines with the greatest potential to reduce antibiotic exposure among children.AUTHOR SUMMARY Because diarrhea is the second-leading cause of antibiotic consumption among children in low- and middle-income countries (LMICs), effective vaccines against diarrheal pathogens may have the collateral benefit of reducing antibiotic exposure and resistance selection in these settings. Whereas antibiotic treatment is only recommended for diarrhea cases with blood in the stool (which suggests Shigella etiology), little is known about real-world diarrhea treatment practices in LMICs. We used data from a study of children experiencing diarrhea and matched, asymptomatic controls residing in LMICs of South Asia and sub-Saharan Africa to understand factors leading to antibiotic treatment of diarrhea cases, and the proportion of cases attributable to various enteric pathogens. We identify rotavirus and Shigella as the predominant causes of antibiotic-treated diarrhea at ages 0-23 months and 24-59 months; additional leading causes include adenovirus serotypes 40/41, sapovirus, Shiga toxin-producing Escherichia coli, and Cryptosporidium. We estimate that approximately 12.6 diarrhea cases receive antibiotics inappropriately for each appropriately-treated case in the study settings. Vaccines against prominent enteropathogens may substantially reduce antibiotic consumption among children in LMICs.Competing Interest StatementJAL has received grants and consulting fees from Pfizer Inc. and Merck, Sharp, & Dohme unrelated to the submitted work. KLK has received grants from Merck, Sharp & Dohme unrelated to the submitted work. All other authors declare no competing interests.Funding StatementThis study was funded by the Bill & Melinda Gates FoundationAuthor DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData from the GEMS1 and GEMS1A studies are available from https://clinepidb.org/ce/app/. https://clinepidb.org/ce/app/